FDA Approves Pfizer-BioNTech COVID-19 Vaccine
FDA Approves Pfizer-BioNTech COVID-19 Vaccine
The milestone marks the first fully-approved COVID-19 vaccine in the United States.
FDA Approves Pfizer-BioNTech COVID-19 Vaccine
FDA Approves Pfizer-BioNTech COVID-19 Vaccine

The milestone marks the first fully-approved COVID-19 vaccine in the United States.

The milestone marks the first fully-approved COVID-19 vaccine in the United States.

Pfizer
Updated
Wealthier Nations Disregarding WHO Call for COVID-19 Booster Moratorium
Wealthier Nations Disregarding WHO Call for COVID-19 Booster Moratorium
Christie Wilcox | Aug 5, 2021
The organization implored nations to wait on booster shots until the global vaccination rate increases, but several of the world’s more well-off countries have expressed their intentions to offer them regardless.
How the Second mRNA Vaccine Bolsters Immunity
How the Second mRNA Vaccine Bolsters Immunity
Annie Melchor | Jul 23, 2021
A study looks beyond T and B cell responses to show how the Pfizer COVID-19 vaccine elicits a strong innate immune response.
COVID-19 Vaccines Appear Safe During Pregnancy: Early Data
COVID-19 Vaccines Appear Safe During Pregnancy: Early Data
Christie Wilcox | Apr 22, 2021
Scientists at the US CDC report no red flags in a preliminary analysis of the safety of Pfizer/BioNTech’s and Moderna’s mRNA-based immunizations among expectant mothers.
Blood Clot Risk from COVID-19 Higher than After Vaccines: Study
Blood Clot Risk from COVID-19 Higher than After Vaccines: Study
Shawna Williams | Apr 16, 2021
The chance of developing cerebral venous sinus thrombosis was nearly 10 times higher in the two weeks following a diagnosis of SARS-CoV-2 infection than after receiving an mRNA vaccine, a data analysis finds.
Pfizer Vaccine Induces Immune Structures Key to Lasting Immunity
Pfizer Vaccine Induces Immune Structures Key to Lasting Immunity
Katarina Zimmer | Mar 25, 2021
In the armpit lymph nodes of people who had received the mRNA vaccine against SARS-CoV-2, researchers found germinal centers needed to generate long-lived antibody-making cells.
COVID-19 Vaccine Combos Aim to Boost Immunity
COVID-19 Vaccine Combos Aim to Boost Immunity
Asher Jones | Mar 9, 2021
Mix-and-match shots could simplify vaccine rollout and stimulate more-robust immune responses. Ongoing clinical trials will soon give answers.
US Authorizes a Third COVID-19 Vaccine
US Authorizes a Third COVID-19 Vaccine
Asher Jones | Mar 1, 2021
Johnson & Johnson’s one-shot immunization could reach people’s arms as early as March 2.
COVID-19 Hospitalizations Tank a Month After Vaccines Roll Out
COVID-19 Hospitalizations Tank a Month After Vaccines Roll Out
Asher Jones | Feb 23, 2021
Two preliminary reports from the UK provide real-world evidence in support of the Pfizer/BioNTech and Oxford-AstraZeneca vaccines.
Pfizer’s COVID-19 Vaccine Reduces Viral Load: Study
Pfizer’s COVID-19 Vaccine Reduces Viral Load: Study
Asher Jones | Feb 10, 2021
Preliminary results from an Israel-based study suggest that one dose of the vaccine reduces infectiousness—a key factor in slowing virus spread.
One-Shot COVID-19 Vaccine Prevents Severe Disease
One-Shot COVID-19 Vaccine Prevents Severe Disease
Asher Jones | Jan 29, 2021
Johnson & Johnson’s vaccine is less effective at preventing COVID-19 than other approved vaccines are, but experts say it could still be an important tool in curbing the pandemic.
Updated
Pfizer’s COVID-19 Vaccine 90 Percent Effective: Initial Data
Pfizer’s COVID-19 Vaccine 90 Percent Effective: Initial Data
Max Kozlov | Nov 9, 2020
Vaccine experts say the results surpass their expectations, but the study is not complete, and the data have not been peer reviewed.
Pharma’s Ghost Labs Find New Life
Pharma’s Ghost Labs Find New Life
Katarina Zimmer | Nov 1, 2019
Finding new tenants for former drug development sites isn’t always easy. But a new, thriving industry has materialized to do just that.
PARP Inhibitors Are Improving the Outlook of Hard-to-Treat Cancers
PARP Inhibitors Are Improving the Outlook of Hard-to-Treat Cancers
Vicki Brower | Apr 1, 2018
With three recent FDA approvals, and a number of Phase 3 trials ongoing, the drugs are seeing a surge in interest.
The Rising Research Profile of 23andMe
The Rising Research Profile of 23andMe
Catherine Offord | Nov 30, 2017
An exploration of the genetics of earlobe attachment is just the latest collaborative research project to come out of the personal genetic testing company.
Pfizer to Buy Medivation for $14 Billion
Pfizer to Buy Medivation for $14 Billion
Bob Grant | Aug 22, 2016
The pharma giant is purchasing the San Francisco–based cancer drugmaker to boost its oncology portfolio.
NYU Halts Studies, Suspends Investigator
NYU Halts Studies, Suspends Investigator
Bob Grant | Jun 28, 2016
Experiments conducted at the New York University School of Medicine violated several research standards, according to US Food and Drug Administration investigators.
Pfizer Scoops Anacor for $5.3 Billion
Pfizer Scoops Anacor for $5.3 Billion
Bob Grant | May 17, 2016
The acquisition-hungry pharmaceutical firm is purchasing the California-based eczema gel maker.
Pfizer-Allergan Merger Scrapped
Pfizer-Allergan Merger Scrapped
Bob Grant | Apr 7, 2016
A move by the US federal government to close tax loopholes that encourage “tax inversions” likely spooked the companies out of the multibillion dollar deal.
Pfizer and Allergan to Merge
Pfizer and Allergan to Merge
Bob Grant | Nov 23, 2015
The two drugmakers will join forces in a $160 billion deal—if it’s given the regulatory green light.